A review of the genus Speocarcinus Stimpson, 1859 (Crustacea: Brachyura: Xanthidae), with a key to its species and the description of one new species

Speocarcinus dentatus n. sp. is described from the southwestern Atlantic. The new species can be easily separated from its congeners by a suite of carapace and appendage characters. Speocarcinus Stimpson, 1859, now includes eight extant species, all from the Atlantic or Pacific coasts of the Americas. Additional characters to further differentiate between S. carolinensis Stimpson, 1859, and S. lobatus Guinot, 1969, and between S. granulimanus Rathbun, 1894, and S. spinicarpus Guinot, 1969 are documented. The lectotype of S. granulimanus is first described and a key to the species of Speocarcinus is provided.

Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis

Whether the two drug-eluting stents approved by the US Food and Drug Administration-a sirolimus-eluting stent and a paclitaxel-eluting stent-are associated with increased risks of death, myocardial infarction, or stent thrombosis compared with bare-metal stents is uncertain. Our aim was to compare the safety and effectiveness of these stents.

Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry.

BACKGROUND The use of transcatheter mitral valve repair (TMVR) has gained widespread acceptance in Europe, but data on immediate success, safety, and long-term echocardiographic follow-up in real-world patients are still limited. OBJECTIVES The aim of this multinational registry is to present a real-world overview of TMVR use in Europe. METHODS The Transcatheter Valve Treatment Sentinel Pilot Registry is a prospective, independent, consecutive collection of individual patient data. RESULTS A total of 628 patients (mean age 74.2 ± 9.7 years, 63.1% men) underwent TMVR between January 2011 and December 2012 in 25 centers in 8 European countries. The prevalent pathogenesis was functional mitral regurgitation (FMR) (n = 452 [72.0%]). The majority of patients (85.5%) were highly symptomatic (New York Heart Association functional class III or higher), with a high logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) (20.4 ± 16.7%). Acute procedural success was high (95.4%) and similar in FMR and degenerative mitral regurgitation (p = 0.662). One clip was implanted in 61.4% of patients. In-hospital mortality was low (2.9%), without significant differences between groups. The estimated 1-year mortality was 15.3%, which was similar for FMR and degenerative mitral regurgitation. The estimated 1-year rate of rehospitalization because of heart failure was 22.8%, significantly higher in the FMR group (25.8% vs. 12.0%, p[log-rank] = 0.009). Paired echocardiographic data from the 1-year follow-up, available for 368 consecutive patients in 15 centers, showed a persistent reduction in the degree of mitral regurgitation at 1 year (6.0% of patients with severe mitral regurgitation). CONCLUSIONS This independent, contemporary registry shows that TMVR is associated with high immediate success, low complication rates, and sustained 1-year reduction of the severity of mitral regurgitation and improvement of clinical symptoms.

Transcatheter aortic valve implantation in failed bioprosthetic surgical valves.

IMPORTANCE Owing to a considerable shift toward bioprosthesis implantation rather than mechanical valves, it is expected that patients will increasingly present with degenerated bioprostheses in the next few years. Transcatheter aortic valve-in-valve implantation is a less invasive approach for patients with structural valve deterioration; however, a comprehensive evaluation of survival after the procedure has not yet been performed. OBJECTIVE To determine the survival of patients after transcatheter valve-in-valve implantation inside failed surgical bioprosthetic valves. DESIGN, SETTING, AND PARTICIPANTS Correlates for survival were evaluated using a multinational valve-in-valve registry that included 459 patients with degenerated bioprosthetic valves undergoing valve-in-valve implantation between 2007 and May 2013 in 55 centers (mean age, 77.6 [SD, 9.8] years; 56% men; median Society of Thoracic Surgeons mortality prediction score, 9.8% [interquartile range, 7.7%-16%]). Surgical valves were classified as small (≤21 mm; 29.7%), intermediate (>21 and <25 mm; 39.3%), and large (≥25 mm; 31%). Implanted devices included both balloon- and self-expandable valves. MAIN OUTCOMES AND MEASURES Survival, stroke, and New York Heart Association functional class. RESULTS Modes of bioprosthesis failure were stenosis (n = 181 [39.4%]), regurgitation (n = 139 [30.3%]), and combined (n = 139 [30.3%]). The stenosis group had a higher percentage of small valves (37% vs 20.9% and 26.6% in the regurgitation and combined groups, respectively; P = .005). Within 1 month following valve-in-valve implantation, 35 (7.6%) patients died, 8 (1.7%) had major stroke, and 313 (92.6%) of surviving patients had good functional status (New York Heart Association class I/II). The overall 1-year Kaplan-Meier survival rate was 83.2% (95% CI, 80.8%-84.7%; 62 death events; 228 survivors). Patients in the stenosis group had worse 1-year survival (76.6%; 95% CI, 68.9%-83.1%; 34 deaths; 86 survivors) in comparison with the regurgitation group (91.2%; 95% CI, 85.7%-96.7%; 10 deaths; 76 survivors) and the combined group (83.9%; 95% CI, 76.8%-91%; 18 deaths; 66 survivors) (P = .01). Similarly, patients with small valves had worse 1-year survival (74.8% [95% CI, 66.2%-83.4%]; 27 deaths; 57 survivors) vs with intermediate-sized valves (81.8%; 95% CI, 75.3%-88.3%; 26 deaths; 92 survivors) and with large valves (93.3%; 95% CI, 85.7%-96.7%; 7 deaths; 73 survivors) (P = .001). Factors associated with mortality within 1 year included having small surgical bioprosthesis (≤21 mm; hazard ratio, 2.04; 95% CI, 1.14-3.67; P = .02) and baseline stenosis (vs regurgitation; hazard ratio, 3.07; 95% CI, 1.33-7.08; P = .008). CONCLUSIONS AND RELEVANCE In this registry of patients who underwent transcatheter valve-in-valve implantation for degenerated bioprosthetic aortic valves, overall 1-year survival was 83.2%. Survival was lower among patients with small bioprostheses and those with predominant surgical valve stenosis.

Una profesión insólita y lucrativa : la captatio testamenti

El presente trabajo se propone: 1. Determinar las distintas formas de testar que adoptó el derecho romano, a lo largo de su evolución histórica. 2. Caracterizar la captatio testamenti, una profesión insólita y lucrativa cuya existencia se constata ya en la Roma republicana, a través del testimonio de Plauto en el Miles gloriosus y que se difundió notablemente durante los primeros siglos del Imperio, en los que se convirtió en un medio de progreso social. 3. Analizar esta actividad desde diferentes perspectivas de acuerdo con los tipos humanos que participan en ella: los captatores testamentorum o heredipetae y los testatores. El corpus trabajado abarca a Plauto (Miles gloriosus), Horacio (Sátira 2,5), Séneca (De beneficiis y Epist. 95), Marcial (Epigramas), Petronio (Satiricón), Juvenal (Sátira 12), Plinio el Viejo (Hist. Natural), Plinio el Joven (Epist. 2, 20).

Petonii Curiosa Felicitas : La función de las citas en el discurso de Eumolpo (Sat. 118)

Este trabajo analiza el fenómeno intertextual de la ?cita? en Petronio, Sat. 118, donde el poeta de la obra, Eumolpo, expone su particular ?ars poetica?. En este discurso, Eumolpo cita los nombres de Homero, Virgilio y Horacio, al tiempo que cita el primer verso de la Oda 3.1 del Venusino, lo que evidencia que el poetastro tiene muy en cuenta la figura horaciana. El análisis de las citas en este pasaje se relaciona con que Petronio es un autor que alude constantemente, pero que cita muy rara vez, por lo que, cuando lo hace, se debe prestar mucha atención

Petonii Curiosa Felicitas : La función de las citas en el discurso de Eumolpo (Sat. 118)

Este trabajo analiza el fenómeno intertextual de la ?cita? en Petronio, Sat. 118, donde el poeta de la obra, Eumolpo, expone su particular ?ars poetica?. En este discurso, Eumolpo cita los nombres de Homero, Virgilio y Horacio, al tiempo que cita el primer verso de la Oda 3.1 del Venusino, lo que evidencia que el poetastro tiene muy en cuenta la figura horaciana. El análisis de las citas en este pasaje se relaciona con que Petronio es un autor que alude constantemente, pero que cita muy rara vez, por lo que, cuando lo hace, se debe prestar mucha atención

Petonii Curiosa Felicitas : La función de las citas en el discurso de Eumolpo (Sat. 118)

Este trabajo analiza el fenómeno intertextual de la ?cita? en Petronio, Sat. 118, donde el poeta de la obra, Eumolpo, expone su particular ?ars poetica?. En este discurso, Eumolpo cita los nombres de Homero, Virgilio y Horacio, al tiempo que cita el primer verso de la Oda 3.1 del Venusino, lo que evidencia que el poetastro tiene muy en cuenta la figura horaciana. El análisis de las citas en este pasaje se relaciona con que Petronio es un autor que alude constantemente, pero que cita muy rara vez, por lo que, cuando lo hace, se debe prestar mucha atención

Saggi filologici.

Bibliographical footnotes.

Petrone latin et françois : traduction entiere suivant le manuscrit trouvé à Belgrade en 1688, avec plusieurs remarques & additions qui manquent dans la premiere edition ; tome premier.

Mode of access: Internet.

Titi Petronii Arbitri Satyricon quae supersunt /

Mode of access: Internet.

Della contemplazione mistica acquistata : opera nouissima in cui si sciogliono l'oppositioni contro à questa oratione /

Mode of access: Internet.

Le Satyricon de T. Pétrone /

Contiene: T. 2.